Gasherbrum Bio Inc. has patented new heterocyclic glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of type 2 diabetes, among others.
Malignant gliomas, which include glioblastomas, are the most frequent primary brain cancer and are associated with extremely poor prognosis. They nearly always recur after treatment, rapidly leading to death.
SHEN-211 is a selective 3-chymotrypsin-like protease (3CLpro) inhibitor that can protect against SARS-CoV-2. In previous work, SHEN-211 demonstrated high efficacy in inhibiting 3CLpro (IC50=24 nM) and exhibited broad-spectrum antiviral properties.
Lung cancer is the most frequent cause of cancer-related death in both men and women worldwide. Current treatments can fail because of variable responses in different types of patients, drug resistance, poor tumor penetration and systemic toxicity, prompting the continuing search for better therapeutics.
Splicing is a process necessary for the correct synthesis of proteins and an essential step in gene expression. An impaired minor splicing may lead to aberrant pre-mRNA transcripts and exon skipping, leading to premature stop codons and truncated synthesized proteins, resulting in severe consequences.
Researchers have identified bi-allelic variants in the POPDC2 gene as the cause of a rare inherited cardiac syndrome characterized by sinus node dysfunction, atrioventricular (AV) conduction defects and hypertrophic cardiomyopathy.
In a recent study published in Nature Genetics, a team of scientists used CRISPR-Cas9 gene editing to systematically analyze genetic weaknesses in uveal melanoma cells and comprehensively map monogenic and digenic dependencies.
SK Bioscience Ltd. announced that the company has submitted an investigational new drug (IND) application to the South Korean Ministry of Food and Drug Safety.
Rhabdomyosarcoma is the most frequent cancer affecting soft tissues in children, and existing therapies often fail to stop relapse or prolong survival. Researchers in Germany and the U.K. have developed a potential new therapy based on natural killer cells expressing a chimeric antigen receptor against epidermal growth factor receptor (EGFR-CAR).
RSS
